LGND (Ligand Pharmaceuticals Incorporated) Net Profit

Corporate emblem and logo of ligand.com (LGND)

Investments in the patent portfolio of Ligand Pharmaceuticals (LGND) ensure supply chain resilience, and the company's financial performance history on GURU.Markets contains data where 0.05 captures the current state of the parameter. The business generates revenue through royalties by providing partners with drug development tools to minimize risks; however, reliance on external contractors forces management to regularly update its pool of manufacturers.

LGND (Ligand) Company Net Income history from 07/04/2022 to 11/01/2026

Financial and market metric breakdowns for Ligand (LGND)

- price and consensus price forecast:
Stock Quotes Ligand Corp|LGND - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Ligand Corp|LGND - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Ligand|LGND - Company Book Value|Market-to-Book Ratio ligand.com|LGND - Cumulative Company Assets
- debt and solvency information:
Aggregate Debt to Capital Ligand Pharmaceuticals|LGND - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Ligand Pharmaceuticals Incorporated|LGND - Company Aggregate Debts|Debts to Book Value Ligand Corp|LGND - Company Long-Term Debt|Company Short-Term Loans and Borrowings Ligand|Quick Liquidity ligand.com
- net income and valuation multiples indicators:
LGND - Net Profit
Fundamental valuation:LGND Ligand Corp
Flagship merchandise of Ligand Pharmaceuticals Incorporated

The monetary result of Ligand Pharmaceuticals (LGND) reflects the effective capitalization of Captisol patents and the protection of its niche through FDA regulatory barriers. This indicator measures daily net profit as the basis for financial stability, where a steady trend confirms business reliability, while stagnation signals a risk of opportunity cost in the absence of profit expansion.

Main competitors

Net Income Haleon Corp|KVUE (Kenvue Inc.) - Net Profit|Net Profit veronapharma.com|Net Income MENS (Jyong Biotech)|AMRX (Amneal Pharmaceuticals, Inc.) - Final Profit|Company Net Income Perrigo Company PRGO|Alvotech Biopharmaceuticals (ALVO) - Company Net Income|LQDA: Net Income|glpg.com - Profit After Payment of Taxes|ANIP: Net Profit|MannKind Corp - Final Profit|AMPH (Amphastar) - Net Profit|Company Net Income Pacira Corp PCRX|Company Net Income ARS Pharmaceuticals (SPRY)|TBPH (theravance.com) - Final Profit|Company Net Income Aquestive Therapeutics, Inc. AQST|scPharmaceuticals, Inc. - Company Net Income|Tectonic - Net Profit|Net Financial Result Tonix Pharmaceuticals Holding TNXP|SXTC: Net Profit|Annual Net Income Eupraxia Pharmaceuticals Inc. EPRX|BHST (BioHarvest Sciences Inc.) - Net Profit|Net Profit Invizyne Technologies|Company Net Income Oramed Pharmaceuticals (ORMP)|enterabio.com - Company Profit|Net Profit HYFT (MindWalk Holdings)|ABVC: Company Profit|CPIX: Net Income|Final Profit QNTM (Quantum BioPharma Ltd.)|FibroGen Corp (FGEN) - Company Net Income|Profit After Tax TELO (Telomir Pharmaceuticals Corp)|RANI (Rani Therapeutics Holdings) - Net Profit|SNYR: Final Profit|Net Profit RLYB|Net Profit lexariabioscience.com (LEXX)|Company Net Income Pulmatrix Corp PULM|Final Profit PTHL|APM - Company Net Income|lyratherapeutics.com (LYRA) - Net Income|IBO: Net Profit|TNF Pharmaceuticals, Inc. (TNFA) - Net Profit|YCBD (cbdMD Inc.) - Net Profit|Net Income PainReform Corp (PRFX)|Net Profit CYTO|LIPO - Company Net Income|OptiNose - Net Income|Net Profit Pieris Pharmaceuticals Inc PIRS|PROC: Net Income|Petros Pharma - Profit After Payment of Taxes|QLI: Net Profit|SLRN - Net Financial Result|TFFP (TFF Pharmaceuticals, Inc.) - Net Profit